CP-690550A

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 524867

CAS#: 1243290-37-0

Description: CP-690550A is a novel JAK3 inhibitor, an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders.

Chemical Structure

img
CP-690550A
CAS# 1243290-37-0
Instruction

Theoretical Analysis

MedKoo Cat#: 524867
Name: CP-690550A
CAS#: 1243290-37-0
Chemical Formula: C15H21N5O2
Exact Mass: 303.17
Molecular Weight: 303.360
Elemental Analysis: C, 59.39; H, 6.98; N, 23.09; O, 10.55

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: CP-690550A; CP-690,550A; CP 690550A; CP690550A; Tofacitinib metabolite M2; UNII-Q7ZOK859UK.

IUPAC/Chemical Name: 2-Hydroxy-1-(4-methyl-3-(methyl-(7hpyrrolo(2,3-d)pyrimidin-4-yl)-amino)-piperidin-1-yl)-ethanone

InChi Key: CCOHWQFOFWCBMH-PWSUYJOCSA-N

InChi Code: InChI=1S/C15H21N5O2/c1-10-4-6-20(13(22)8-21)7-12(10)19(2)15-11-3-5-16-14(11)17-9-18-15/h3,5,9-10,12,21H,4,6-8H2,1-2H3,(H,16,17,18)/t10-,12+/m1/s1

SMILES Code: C[C@@H]1CCN(C[C@@H]1N(C)c2c3cc[nH]c3ncn2)C(=O)CO

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 303.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Yamaoka K. Relation between disease modifying anti-rheumatic drugs and herpes zoster in rheumatoid arthritis. Nihon Rinsho Meneki Gakkai Kaishi. 2016;39(3):181-9. doi: 10.2177/jsci.39.181. PubMed PMID: 27320933.

2: Radominski SC, Cardiel MH, Citera G, Goecke A, Jaller JJ, Lomonte AB, Miranda P, Velez P, Xibillé D, Kwok K, Rojo R, García EG. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies. Reumatol Clin. 2016 Jun 14. pii: S1699-258X(16)30040-7. doi: 10.1016/j.reuma.2016.04.010. [Epub ahead of print] English, Spanish. PubMed PMID: 27317492.

3: Tanaka Y. [Tofacitinib for the treatment of rheumatoid arthritis]. Nihon Rinsho. 2016 Jun;74(6):974-80. Japanese. PubMed PMID: 27311188.

4: Sterba Y, Ilowite N. Biologics in Pediatric Rheumatology: Quo Vadis? Curr Rheumatol Rep. 2016 Jul;18(7):45. doi: 10.1007/s11926-016-0593-9. Review. PubMed PMID: 27306623.

5: Gupta AK, Carviel JL, Abramovits W. Efficacy of tofacitinib in treatment of alopecia universalis in two patients. J Eur Acad Dermatol Venereol. 2016 Jun 15. doi: 10.1111/jdv.13598. [Epub ahead of print] PubMed PMID: 27306107.

6: Clowse ME, Feldman SR, Isaacs JD, Kimball AB, Strand V, Warren RB, Xibillé D, Chen Y, Frazier D, Geier J, Proulx J, Marren A. Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis. Drug Saf. 2016 Jun 9. [Epub ahead of print] PubMed PMID: 27282428.

7: Valenzuela F, Paul C, Mallbris L, Tan H, Papacharalambous J, Valdez H, Mamolo C. Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study. J Eur Acad Dermatol Venereol. 2016 Jun 7. doi: 10.1111/jdv.13702. [Epub ahead of print] PubMed PMID: 27271195.

8: Galluzzo M, D'Adamio S, Servoli S, Bianchi L, Chimenti S, Talamonti M. Tofacitinib for the treatment of psoriasis. Expert Opin Pharmacother. 2016 Jul;17(10):1421-33. doi: 10.1080/14656566.2016.1195812. PubMed PMID: 27267933.

9: Damsky WE, Choi J. Genetics of Cutaneous T Cell Lymphoma: From Bench to Bedside. Curr Treat Options Oncol. 2016 Jul;17(7):33. doi: 10.1007/s11864-016-0410-8. Review. PubMed PMID: 27262707.

10: Iwata S, Tanaka Y. Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2016 Jun 6:1-11. [Epub ahead of print] PubMed PMID: 27253519.

11: Tran CT, Ducancelle A, Masson C, Lunel-Fabiani F. Herpes zoster: Risk and prevention during immunomodulating therapy. Joint Bone Spine. 2016 May 27. pii: S1297-319X(16)30052-5. doi: 10.1016/j.jbspin.2016.04.001. [Epub ahead of print] PubMed PMID: 27245419.

12: Xie F, Yun H, Bernatsky S, Curtis JR. Risk for Gastrointestinal Perforation among Rheumatoid Arthritis Patients receiving Tofacitinib, Tocilizumab, or other Biologics. Arthritis Rheumatol. 2016 May 23. doi: 10.1002/art.39761. [Epub ahead of print] PubMed PMID: 27213279.

13: Anzengruber F, Maul JT, Kamarachev J, Trüeb RM, French LE, Navarini AA. Transient Efficacy of Tofacitinib in Alopecia Areata Universalis. Case Rep Dermatol. 2016 Apr 22;8(1):102-6. doi: 10.1159/000445182. eCollection 2016 Jan-Apr. PubMed PMID: 27194979; PubMed Central PMCID: PMC4869306.

14: Panés J, Su C, Bushmakin AG, Cappelleri JC, Healey P. Direct and Indirect Effects of Tofacitinib on Treatment Satisfaction in Patients with Ulcerative Colitis. J Crohns Colitis. 2016 May 18. pii: jjw107. [Epub ahead of print] PubMed PMID: 27194530.

15: Yamaoka K. Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster. Drug Saf. 2016 May 18. [Epub ahead of print] Review. PubMed PMID: 27193610.

16: Louder AM, Singh A, Saverno K, Cappelleri JC, Aten AJ, Koenig AS, Pasquale MK. Patient Preferences Regarding Rheumatoid Arthritis Therapies: A Conjoint Analysis. Am Health Drug Benefits. 2016 Apr;9(2):84-93. PubMed PMID: 27182427; PubMed Central PMCID: PMC4856233.

17: Izzo R, Bevivino G, Monteleone G. Tofacitinib for the treatment of ulcerative colitis. Expert Opin Investig Drugs. 2016 May 30:1-7. [Epub ahead of print] PubMed PMID: 27177233.

18: Singh JA, Hossain A, Tanjong Ghogomu E, Kotb A, Christensen R, Mudano AS, Maxwell LJ, Shah NP, Tugwell P, Wells GA. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2016 May 13;(5):CD012183. doi: 10.1002/14651858.CD012183. Review. PubMed PMID: 27175934.

19: Piscianz E, Candilera V, Valencic E, Loganes C, Paron G, De Iudicibus S, Decorti G, Tommasini A. Action of methotrexate and tofacitinib on directly stimulated and bystander-activated lymphocytes. Mol Med Rep. 2016 Jul;14(1):574-82. doi: 10.3892/mmr.2016.5263. Epub 2016 May 13. PubMed PMID: 27175898.

20: Fleischmann R, Strand V, Wilkinson B, Kwok K, Bananis E. Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-naïve patients with rheumatoid arthritis. RMD Open. 2016 Apr 26;2(1):e000232. doi: 10.1136/rmdopen-2015-000232. eCollection 2016. PubMed PMID: 27175296; PubMed Central PMCID: PMC4860866.